This summary was created by AI, based on 1 opinions in the last 12 months.
Natera (NTRA-Q) has experienced substantial growth over the past year, with its stock price rising by 145%. This impressive performance has caught the attention of various analysts and experts. The company has established a strong footprint in the field of cancer detection, particularly in monitoring recurrence of the disease, which is a critical area in oncology. Many view this focus as a promising long-term strategy, which could lead to sustained growth and further innovation in healthcare solutions. As a result, the analysts have trimmed their reservations and seem optimistic about Natera's future prospects, advocating for a long-term investment in the company's stock.
A biotech that does, among other things, cancer testing which is very accurate.. She just bought it. Is growing fast and expects it to be cash-flow positive this year.
Natera is a American stock, trading under the symbol NTRA-Q on the NASDAQ (NTRA). It is usually referred to as NASDAQ:NTRA or NTRA-Q
In the last year, 2 stock analysts published opinions about NTRA-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Natera.
Natera was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Natera.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Natera In the last year. It is a trending stock that is worth watching.
On 2025-03-20, Natera (NTRA-Q) stock closed at a price of $149.63.
Trimmed it because it moved up 145% the past year. They have a great franchise in cancer detection recurrence. Likes it long-term.